How much umbrella (excess) liability does a life sciences company need?

An umbrella (or excess) liability policy sits on top of an operator's primary lines - commercial general liability, products and completed operations, commercial auto, and employers liability under workers compensation - and provides additional limits once those underlying policies are exhausted. For a true umbrella, it can also "drop down" to respond where an underlying policy has a gap, subject to the umbrella's own terms.

For life sciences operators, the umbrella is rarely bought to a generic number. It is built to reach a specific total limit that a sponsor, hospital, or GPO contract requires, and to provide a catastrophic backstop for the one exposure that can exceed primary limits - products and completed operations bodily injury from a drug, device, or compounded preparation.

The correct way to size umbrella for a CDMO, CRO, biotech, medical device manufacturer, or 503B is to read the insurance schedules in the operator's actual contracts and build to the highest total limit any of them require. Sponsor MSAs in oncology, sterile injectable, biologics, and controlled-substance manufacturing, and hospital purchase contracts for higher-risk implantables, increasingly require $10M-$25M in total per-occurrence and aggregate limits. Mid-market operators on standard sponsor work commonly need $5M-$10M.

Because primary general liability and products typically cap at $1M/$2M, the operator reaches the contract total by stacking an umbrella (and, above it, additional excess layers) over the primary. A $10M contract requirement is usually met with a $1M/$2M primary plus a $9M-$10M umbrella/excess tower.

A common and expensive misconception is that the umbrella backstops everything. It does not. Umbrella and excess liability extend the operator's general liability, products, auto, and employers liability - they do not extend directors and officers (D&O) liability, professional liability or errors and omissions (E&O), or cyber liability. Those management- and professional-liability lines carry their own limits and, where higher limits are needed, their own excess layers.

For a biotech, this means the $10M umbrella over the products tower does nothing for a securities or governance claim against the board - that exposure lives in the D&O program. For a CRO, the umbrella does not lift the professional liability limit for a trial-execution error. Operators should confirm which underlying lines the umbrella schedules and which it does not.

Clinical-stage biotech with no commercial product: often $5M total is sufficient for landlord and general operations, with the heavier limits concentrated in D&O and clinical trial liability rather than the umbrella over general liability. Mid-market CDMO or CRO on sponsor MSAs: commonly $5M-$10M total, driven by the sponsor schedule. 503B outsourcing facility and higher-risk medical device manufacturer: commonly $10M-$25M, driven by hospital purchase contracts and the batch-level or implantable severity profile.

Premium for the umbrella layer scales with the underlying exposure and the attachment point; a clean $9M umbrella over a mid-market CDMO products tower is a modest fraction of the primary products premium, and is almost always cheaper than discovering at a claim that the program could not reach the contract limit.

The single most common umbrella failure in life sciences is a tower that does not follow form over products and completed operations at its upper layers. If a higher excess layer reverts to its own narrower terms rather than following the primary products wording, the operator can have the limit on paper but not the coverage at a real products claim. The schedule of underlying and the follow-form status of each layer should be confirmed at binding, not assumed.